Assumption testing in population pharmacokinetic models: Illustrated with an analysis of moxonidine data from congestive heart failure patients

被引:122
作者
Karlsson, MO
Jonsson, EN
Wiltse, CG
Wade, JR
机构
[1] Univ Uppsala, Dept Pharm, S-75123 Uppsala, Sweden
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Swedish Med Prod Agcy, Uppsala, Sweden
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1998年 / 26卷 / 02期
关键词
population pharmacokinetics; validation; moxonidine;
D O I
10.1023/A:1020561807903
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Deriving a population pharmacokinetic model from real data is always associated with numerous assumptions. Violations of these assumptions, especially if undetected, may lead to inappropriate conclusions being made from the analysis. Routinely, only a few of the assumptions are explicitly stated and justified in the reporting of a population model. Here, we attempt to be exhaustive in the presentation of the assumptions made in the course of an analysis of moxonidine pharmacokinetics. The different ways that assumptions were justified, through experience, graphical examination, or additional modeling, are outlined. Models for relaxing assumptions regarding the covariate and statistical submodels, not previously reported in the area of population pharmacokinetic modeling, are also described.
引用
收藏
页码:207 / 246
页数:40
相关论文
共 28 条
[1]   Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies [J].
Aarons, L ;
Balant, LP ;
Mentre, F ;
Rowland, M ;
Steimer, JL ;
Vozeh, S .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) :251-254
[2]  
Aarons L., 1997, POPULATION APPROACH
[3]  
BEAL SL, 1992, NONMEM USERS GUIDES
[4]   A comparison of a Bayesian population method with two methods as implemented in commercially available software [J].
Bennett, JE ;
Wakefield, JC .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (04) :403-432
[5]   Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis [J].
Bruno, R ;
Vivier, N ;
Montay, G ;
LeLiboux, A ;
Powe, LK ;
Delumeau, JC ;
Rhodes, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :518-526
[6]   POPULATION PHARMACOKINETICS OF MIDAZOLAM IN NEONATES [J].
BURTIN, P ;
JACQZAIGRAIN, E ;
GIRARD, P ;
LENCLEN, R ;
MAGNY, JF ;
BETREMIEUX, P ;
TEHIRY, C ;
DESPLANQUES, L ;
MUSSAT, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (06) :615-625
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]  
Davidian M, 1993, J Biopharm Stat, V3, P23, DOI 10.1080/10543409308835047
[9]   EXPERIMENTAL-DESIGN AND EFFICIENT PARAMETER-ESTIMATION IN PRECLINICAL PHARMACOKINETIC STUDIES [J].
ETTE, EI ;
HOWIE, CA ;
KELMAN, AW ;
WHITING, B .
PHARMACEUTICAL RESEARCH, 1995, 12 (05) :729-737
[10]   POPULATION PHARMACOKINETICS OF QUINIDINE [J].
FATTINGER, K ;
VOZEH, S ;
HA, HR ;
BORNER, M ;
FOLLATH, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (03) :279-286